An interventional study of Control Diet and Diverse Diet in Healthy and Overweight (BMI > 25), sponsored by University of Kiel. Not yet recruiting at 1 site in Germany. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by University of Kiel · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies in Overweight with a site in Germany — 40 open to participants now, 62 under way, 34 of them phase 3. Overweight · Germany.
Among the 151 studies in Overweight with a site in Germany, this one is the 124th largest by planned enrollment of the 142 interventional ones that give a count, is one of 2 that started in 2027, is one of 53 with no phase, reaches primary completion later than 57 of the 61 other live ones, and was the 149th registered.
3,613 studies on the registry are indexed under Overweight; 856 are open to participants now.
Browse Overweight studies →40 of the 151 studies in Overweight with a site in Germany are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Germany, United States, Brazil and 7 more countries
Ages 18+
German Diabetes Center · Sites in Germany
Ages 19–75
Novo Nordisk A/S · Sites in Germany
Ages 18+
Boehringer Ingelheim · Sites in Germany
Ages 18–74
Buchinger Wilhelmi Development & Holding GmbH · Sites in Germany
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 531 Overweight studies recruiting now, 159 (30%) set no upper age limit and 344 (65%) stop at 75 or younger; 63 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 10 · Phase 3 48 · Phase 4 6
First in 2004; this study’s year is marked. 2 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 34 is below the median of 78 across 3,127 interventional studies indexed under Overweight.
Median enrollment 131 across the 142 interventional studies, 300 across the 9 observational. Of the 81 that completed or were terminated, 13 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
97 of 151 have an industry lead sponsor. The 10 most frequent:
University of Kiel is the lead sponsor of 26 studies on the registry; 7 are open to participants now.
University of Kiel has 1 study filed under Overweight — fewer than ten, so there is no comparison to draw.
24 of the studies in Overweight with a site in Germany that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
Add all 24 to your calendar (.ics) → With an account.
Among the 151 studies in Overweight with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized, controlled, crossover dietary intervention will test whether a three-week diverse diet, compared with a control diet with lower food diversity, changes postprandial insulin responses, other metabolic parameters, and the gut microbiome in 34 healthy adults with overweight. Participants will complete both diets in a randomized order, separated by a four-week washout period. The intervention periods will be conducted under free-living conditions, with study foods provided by the research center. Before and after each intervention period, postprandial metabolism will be assessed using standardized meal tests conducted under controlled whole-room calorimetry conditions. The primary outcome is the log-transformed total postprandial insulin area under the concentration-time curve from 0 to 240 minutes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Control Diet · Other: Diverse Diet
Other: Control Diet · Other: Diverse Diet
Three-week controlled free-living diet with low diversity of plant foods, lower diversity/content of fiber types and polyphenols, fewer fermented foods, and at least 50% of energy from ultra-processed foods. The diet is designed to follow German Nutrition Society recommendations and to be as comparable as possible to a diverse diet.
Three-week controlled free-living diet with a wide variety of minimally processed plant foods, different fiber types and polyphenol sources, and regularly consumed fermented foods. The diet is designed to follow German Nutrition Society recommendations and to be as comparable as possible to the control diet.
Postprandial Insulin
fasting, iAUC, tAUC, peak - measured using a meal test conducted in a whole-room indirect calorimeter at the beginning and end of each three-week intervention period, i.e., twice per intervention.
Time frame: 0-240 minutes
Postprandial Glucose
fasting, iAUC, tAUC, peak - measured using a meal test conducted in a whole-room indirect calorimeter at the beginning and end of each three-week intervention period, i.e., twice per intervention.
Time frame: 0-240 minutes
C-Peptide
Urinary c-peptide excretion during the 24h stay in the whole-room indirect calorimeter.
Time frame: 24 hours
Non-esterified fatty acids
fasting, iAUC, tAUC - measured using a meal test conducted in a whole-room indirect calorimeter at the beginning and end of each three-week intervention period, i.e., twice per intervention.
Time frame: 0-240 minutes
Triglycerides
fasting, iAUC, tAUC - measured using a meal test conducted in a whole-room indirect calorimeter at the beginning and end of each three-week intervention period, i.e., twice per intervention.
Time frame: 0-240 minutes
Appetite-relatied hormones (GLP-1, PYY, Ghrelin)
fasting, iAUC, tAUC - measured using a meal test conducted in a whole-room indirect calorimeter at the beginning and end of each three-week intervention period, i.e., twice per intervention.
Time frame: 0-240 minutes
Subjective Appetite
measured with visual analogue scales (5 hours AUC; mm x 5 hours) after a meal test conducted in a whole-room indirect calorimeter at the beginning and end of each three-week intervention period, i.e., twice per intervention. The scale consists of a 10 cm vertical line anchored with "not hungry at all" at the left side and with "extremely hungry" at the right side.
Time frame: 0-300 minutes
Energy Expenditure and macronutrient oxidation
measured during the 24h stay with indirect calorimetry in a whole-room indirect calorimeter (kcal/day) at the beginning and end of each three-week intervention period, i.e., twice per intervention.
Time frame: 24 hours
Gut microbiome composition and Microbiome diversity
taxonomy and function via shotgun metagenome sequencing
Time frame: Baseline, after 1 week in the intervention (day 8), after the 3-week intervention (day 21) - in both arms.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Feb 2027; primary completion for Sep 2029, 31 months later.
Of 1,305 non-industry interventional studies with no phase under Overweight, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's planned 31 months is above that.
Counting every sponsor, half of 1,417 studies reached it within 17 months; a quarter within 8 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Kiel